Autonomous Patient Monitoring To Be The Center-Stage Of The Sleep Aids Market At A CAGR Of 4.5%

The global Sleep Aids Market is all set to witness a CAGR of 4.5% in the next decade. It is expected to reach US$ 40.1 Mn by the year 2031. With digitized communication channels making a beeline to the healthcare vertical, the advanced clinics are into virtual consultation mode, and this scenario is expected to continue even going forward. Regulatory approvals for this type of communication are on the way. Close to 70% of the public hospitals worldwide are being asked to adopt digital means. This would be the scene with the healthcare vertical in the subsequent period.

As per Persistence Market Research's latest revised industry analysis, the global sleep aids market was valued at over US$ 24.6 Bn in 2020, and is expected to exhibit a CAGR of close to 4.5% over the forecast period (2021-2031).

Increasing prevalence of sleep-related disorders, changing lifestyles, obesity, and increasing aging population, together with technology advancements with the launch of innovative devices are some of the factors driving demand for sleep aids.

Get Free Sample Of Sleep Aids Market Report@ https://www.persistencemarketresearch.com/samples/2832

Increasing demand for sleeping pills due to modern lifestyles is one of the major factor driving demand for sleep aids. Stressful pace of life is found to be the main characteristic of modern lifestyle, thus increasing the incidence of sleep-related disorders. According to the Centers for Disease Control and Prevention (CDC) 2020 report, one-third of the U.S. population gets less than the recommended amount of sleep on a regular basis.

Company Profiles:
• ResMed Inc.
• Royal Philips NV
• Merck & Co. Inc.
• Drive DeVilbiss Healthcare LLC
• GlaxoSmithKline Plc.
• Fisher & Paykel Healthcare Limited
• Sanofi SA
• Pfizer Inc

Look Through The "Methodology" Employed@ https://www.persistencemarketresearch.com/methodology/2832

Key Takeaways from Market Study
• By product, mattresses and pillows, chin straps, mouth pieces, and nasal devices will hold a market share of 72.5% in 2021, expanding at a CAGR of around 4.3% over the forecast period.
• By indication, insomnia is expected to hold well over 35% market share in 2021, and is expected to continue growing at a moderate rate over the forecast period.
• By distribution channel, the e-Commerce and others segments together holds more than 50% market share, and are expected to continue a similar trend through the forecast period.
• By region, North America held the highest share in the global market in 2020, with the market expanding at a CAGR of nearly 4%.

"Growing incidence of sleeping disorders and rising need for technologically advanced products for their treatment are expected to drive market growth over the forecast period," says an analyst of Persistence Market Research.

Market Competition
New product launches and acquisitions have emerged as a key growth strategy adopted by some of the leading manufacturers of sleep aids. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.

• 04-Feb-2020, Merck & Co/MSD claimed FDA approval for a new use of its insomnia drug Belsomra, treating sleep disruption in people with mild-to-moderate Alzheimer's disease.
• In January 2019, GSK announced that it completed the acquisition of Tesaro for approximately US$ 5.1 Bn.
• In 2018, Philips acquired NightBalance, a digital health company in the Netherlands, which has developed an innovative, easy-to-use device to treat positional obstructive sleep apnea and positional snoring.
• In August 2017, Sanofi S.A. announced the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, Connecticut, in the United States.

What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the sleep aids market in its latest study, presenting historical demand assessment of 2016 - 2020 and projections for 2021 - 2031.

The research study is based on product (drugs {insomnia treatment drugs [doxepin hydrochloride, eszopiclone, ramelteon, triazolam, zaleplon, quazepam, and others], narcolepsy treatment drugs [modafinil, sodium oxybate, armodafinil, and others]}, devices {CPAP devices, BIPAP devices, and APAP devices}, others {mattresses & pillows, chin straps, nasal devices and mouthpieces}), by indication (insomnia, sleep deprivation, narcolepsy, sleep apnea, and others), and distribution channel (hospital pharmacies, retail pharmacies, e-Commerce, drug stores, and others), across five key regions of the world.

Purchase Our Sleep Aids Market Report Now@ https://www.persistencemarketresearch.com/checkout/2832

Contact Us:
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.